ALLO

Allogene Therapeutics, Inc. Common Stock · XNAS · 131 sessions on record

$1.60▼ −0.02 · −1.2%from $1.62 the session before · Sep 30, 2026 close · end of day

Open: $1.61
High: $1.66
Low: $1.58
Day's range: $0.084.9% of the previous close
VWAP: $1.61close −0.59% from it
Volume, shares: 8.13M1.43× the 20-session average
Traded, $: $13.1M
Trades: 16.2K500 shares per trade
Previous close: $1.62−0.02 to the close
Market cap: $552.8Mat the close of Sep 30

Day range25% of the way up

$1.58$1.66

52-week range1% of the way up

$1.58 Sep 30$4.46 Apr 13

−64% from the high · +1.3% from the low

Options

No listed options on ALLO

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

131 sessions on file · from Mar 25

ALLO close
S&P 500, rebased

Session read · latest close: Sep 30, 2026
Close $ · day %: $1.60▼ −1.2% on the previous close
Against S&P 500: S&P 500 −0.2%−1.0 pp difference on the day
Against the averages: below 20 · below 5020-session $1.75 (−8.3%) · 50-session $1.89 (−15%)
Volume: 1.43×the previous 20 sessions · 8.13M shares
Extremes on the day: lowest close in 250 sessions

Quarterly results

consolidated · latest filed Aug 12, 2026 · SEC filings

Revenue $4.6M; profit −$42.7M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session

Quarterly results of ALLO on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $	Market on the day
Jun 2026filed Aug 12	$4.6M	—	−$42.7M	—	-0.13	▼ −4.3%S&P 500 +0.7% · −5.0 pp
Mar 2026filed Aug 12	—	—	−$42.6M	—	-0.18	▼ −4.3%S&P 500 +0.7% · −5.0 pp
Dec 2025filed Mar 12	$0	—	−$38.8M	—	-0.17	—not reached
Sep 2025filed Nov 6	$0	—	−$41.4M	—	-0.19	—not reached
Jun 2025filed Aug 12	$0	—	−$50.9M	—	-0.23	▼ −4.3%S&P 500 +0.7% · −5.0 pp
Mar 2025filed Aug 12	$0	▼ −100%	−$59.7M	—	-0.28	▼ −4.3%S&P 500 +0.7% · −5.0 pp
Dec 2024filed Mar 13	$0	▼ −100%	−$59.9M	—	-0.27	—not reached
Sep 2024filed Nov 6	$0	▼ −100%	−$66.3M	—	-0.32	—not reached

By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends

Financial-year results of ALLO on the consolidated basis, summed from the quarters filed
Year	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $
FY25to Dec 2025	$0	▼ −100%	−$190.9M	—	-0.87
FY24to Dec 2024	$22.0K	▼ −77%	−$257.6M	—	-1.32
FY23to Dec 2023	$95.0K	▼ −39%	−$327.3M	—	-2.09
FY22to Dec 2022	$156.0K	▼ −100%	−$340.4M	—	-2.38
FY21to Dec 2021	$114.1M	—	−$182.1M	—	-1.34

Fundamentals

consolidated · filings to Jun 2026 · close $1.60 on Sep 30

1.3 times book value, market cap $552.8M.

Valuation

Market cap: $552.8Mon Sep 30
Price to earnings: —
Trailing EPS: $-0.67diluted · consolidated · four quarters to Jun 2026
Price to book: 1.3consolidated · balance sheet to Jun 2026
Book value a share: $1.26consolidated · balance sheet to Jun 2026
Debt to equity: —
Return on equity: -42%trailing profit over average equity · consolidated
Dividend yield: —
Price to sales: —
Shares outstanding: 345Mon Sep 30

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: —
Revenue growth, 12 months: —
Revenue 3-year CAGR: —trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months: −$165.5Mfour quarters to Jun 2026
Profit growth, 12 months: —
Profit 3-year CAGR: —

PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap

Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
Stock	Market cap	P/E	P/B	Close $
MRNAModerna, Inc. Common Stock	$76.88Bon Sep 30	—	11	$192.57
HALOHalozyme Therapeutics, Inc.	$12.53Bon Sep 30	32consolidated	87	$110.40
TECHBio-Techne Corp.	$11.36Bon Sep 30	62consolidated	5.4	$72.47
KODKodiak Sciences Inc Common Stock	$5.96Bon Sep 30	—	98	$94.80
ALLOAllogene Therapeutics, Inc. Common Stock	$552.8Mon Sep 30	—	1.3	$1.60
DTILPrecision BioSciences, Inc. Common Stock	$172.8Mon Sep 30	—	3.8	$6.26
OTLKOutlook Therapeutics, Inc. Common Stock	$139.6Mon Sep 30	—	—	$0.57
BSEMBioStem Technologies, Inc. Common Stock	$55.2Mon Sep 30	—	2.0	$3.09
TVGNTevogen Inc. Common Stock	$43.1Mon Sep 30	—	—	$6.62
BCDABioCardia, Inc. Common Stock	$15.3Mon Sep 30	—	5.7	$1.01

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 180% of shares, BlackRock, Inc. the largest at 17%, Frazier Life Sciences Management, L.P. 13% and Pfizer Inc 13%, as filed for the quarter to Jun 2026.

17.4%13.0%12.8%133.8%

Held by 13F managers: 180%of shares outstanding
Shares held: 611M+61% on Mar 2026 among managers filing both
Managers holding: 196192 a quarter earlier
Largest holder: 17%BlackRock, Inc.

Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter

Largest 13F holders of ALLO
Manager	Shares	Of outstanding	Value	Change on quarter
BlackRock, Inc.	60.3M	17%	$125.4M	+22.1M
Frazier Life Sciences Management, L.P.	44.9M	13%	$93.4M	+37.3M
Pfizer Inc	44.1M	13%	$93.9M	unchanged
STATE STREET CORP	38.1M	11%	$79.1M	+20.7M
TPG GP A, LLC	37.4M	11%	$77.9M	unchanged
Sio Capital Management, LLC	26.6M	7.7%	$55.4M	—
PRIMECAP MANAGEMENT CO/CA/	26.2M	7.6%	$54.6M	+9.49M
VANGUARD CAPITAL MANAGEMENT LLC	24.3M	7.0%	$50.6M	+10.5M
FMR LLC	24M	7.0%	$50.0M	+20.8M
CITADEL ADVISORS LLC	20.2M	5.8%	$42.0M	+6.59M

Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

ALLO insider trades
Insider	Trade	Shares	Price	Held after
Kazam Joshua ADirector	exercised · Jun 18, 2026	47,700	$0.00	398,463
Yoshiyama AnnieOfficer	sold · Apr 21, 2026	9,586	$2.31	124,517
Beneski Benjamin MachinasOfficer	sold · Mar 31, 2026	2,867	$2.50	195,338
Chang David DDirector,Officer	sold · Mar 16, 2026	47,763	$2.47	5,150,599
Beneski Benjamin MachinasOfficer	sold · Mar 16, 2026	4,835	$2.47	198,205
Beneski Benjamin MachinasOfficer	sold · Mar 2, 2026	7,132	$2.60	203,040
Douglas Earl MartinOfficer	sold · Feb 2, 2026	22,900	$1.76	564,948
Roberts ZacharyOfficer	sold · Feb 2, 2026	35,700	$1.77	581,166
Yoshiyama AnnieOfficer	sold · Feb 2, 2026	4,167	$1.72	130,322
Parker Geoffrey M.Officer	sold · Feb 2, 2026	24,001	$1.76	1,252,795

Corporate actions

exchange records

No corporate action on record for ALLO yet.

Price history

131 sessions on record · to Sep 30 · end of day

ALLO is −19.4% over 20 sessions against the S&P 500's +0.1%, 64% below its 52-week high, realised volatility 37% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions

Returns of the stock and S&P 500 over six windows, longest first
Window	From $	ALLO %	S&P 500 %	Difference pp
120 sessionssince Apr 9	$2.91	▼ −45%	▲ +12%	−57
60 sessionssince Jul 7	$2.15	▼ −26%	▲ +2.0%	−28
20 sessionssince Sep 1	$1.99	▼ −19%	▲ +0.11%	−20
5 sessionssince Sep 23	$1.67	▼ −4.2%	▼ −0.67%	−3.5
1 sessionsince Sep 29	$1.62	▼ −1.2%	▼ −0.21%	−1.0

Averages of the closeclose against each average

5-session average: $1.63close −1.8% from it
20-session average: $1.75close −8.6% from it
50-session average: $1.89close −15% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: $0.084.8% of the close
Average day's range, 20: $0.074.7% of the close
Volume against 20 sessions: 1.43×8.13M vs 5.88M average

Volatility and co-movement with S&P 500annualised from daily returns

Realised volatility, 20: 37%≈ ±2.3% a session · moved more than that on 4 of 20
Realised volatility, 60: 58%≈ ±3.6% a session · moved more than that on 17 of 60
Beta to S&P 500, 60: 1.12moved with S&P 500 on 32 of 60 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 4 up · 12 downof 16
Last 60 sessions: 21 up · 34 downof 55
Best session, 250: ▲ +13%Apr 13
Worst session, 250: ▼ −25%Apr 14

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 46% of reported volume on Sep 30, 2026, against 59% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume

ALLO daily short-sale volume
Session	Short volume	Reported volume	Short share
Sep 30, 2026	1.05M	2.3M	45.5%
Sep 29, 2026	850K	1.84M	46.1%
Sep 28, 2026	1.36M	3.33M	40.8%
Sep 25, 2026	1.33M	2.13M	62.5%
Sep 24, 2026	3.23M	4.66M	69.2%
Sep 23, 2026	2.12M	3.35M	63.3%
Sep 22, 2026	1.32M	2.41M	54.8%
Sep 21, 2026	1.58M	2.54M	62.4%
Sep 18, 2026	1.63M	2.72M	59.8%
Sep 17, 2026	1.62M	2.44M	66.3%

Filings

SEC EDGAR · newest first

ALLO SEC filings
Filed	Form	Report date
Sep 30, 2026	SCHEDULE 13D/A	—
Sep 2, 2026	8-K	Aug 31, 2026
Aug 25, 2026	4	Aug 21, 2026
Aug 21, 2026	144	—
Aug 20, 2026	EFFECT	—
Aug 14, 2026	SCHEDULE 13G/A	—
Aug 12, 2026	S-3	—
Aug 12, 2026	10-Q	Jun 30, 2026
Aug 12, 2026	8-K	Aug 12, 2026
Aug 7, 2026	SCHEDULE 13G/A	—
Aug 7, 2026	SCHEDULE 13G	—
Jul 6, 2026	4	Jul 1, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 23, 2026	4	Jun 18, 2026
Jun 22, 2026	8-K	Jun 18, 2026
Jun 22, 2026	424B5	—
May 28, 2026	DEFA14A	—
May 28, 2026	8-K	May 28, 2026
May 21, 2026	DEFA14A	—
May 15, 2026	SCHEDULE 13G/A	—

About Allogene Therapeutics, Inc. Common Stock

SEC and exchange records

Company: Allogene Therapeutics, Inc. Common Stock
Exchange: XNAS
Industry: Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK: 1737287
Sessions on record: 131
Price source: End of day · delayed
Computed: 1 Oct, 10:42 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.